UCB Arthritis Drug Achieves Strong Results in Phase III
Posted on: Sunday, 17 June 2007, 21:02 CDT
Belgian pharmaceutical company UCB has revealed that its rheumatoid arthritis drug Cimzia combined with standard methotrexate therapy significantly reduces symptoms of the disease compared with methotrexate alone.
Data from the study also showed that Cimzia given every four weeks as monotherapy is significantly more efficacious than placebo in the treatment of patients with active rheumatoid arthritis (RA) who had previously failed disease-modifying anti-rheumatic drug therapy.
In two phase III studies, response levels were significantly higher in both Cimzia treated arms (400mg at week zero, week two and week four followed by 200mg every two weeks plus methotrexate; or 400mg every two weeks plus methotrexate) compared with the placebo plus methotrexate-treated arm, the company said.
UCB also said that effective results in the treatment of RA can be achieved with a 200mg every other week dose of Cimzia - the higher dose is not necessary. The safety and tolerability profile of Cimzia in both studies was consistent with that expected of an anti-TNF agent.
Preparation for a regulatory submission for Cimzia in the treatment of RA is ongoing, with filing planned by the end of 2007.
Source: Datamonitor
Related Articles
- Light Reading Weekly's Picks of the Week
- UCB's Cimzia(R) Filed With EMEA for Treatment of Rheumatoid Arthritis
- Valeant Pharmaceuticals Reports Encouraging Phase IIb Results at Treatment Week 12 for Taribavirin
- CIMZIA(R) (Certolizumab Pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year
- TMC125 Showed Significant Virologic Response at Week 24 in Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3 Trials
- AMG Scientific, LLC Unveils Protection Plus Treatment Demonstration Video
- Study Explores Use of PROCRIT(R) (Epoetin Alfa) Once Every Two Weeks As Initiation Treatment for Chemotherapy-Related Anemia
- Study: Hospitals Significantly Improve Treatment of Heart Attacks, Heart Failure, and Pneumonia
- Abbott Presents Promising Phase III Data for HUMIRA(R) (Adalimumab) Plus Methotrexate As First-Line Treatment in Early Rheumatoid Arthritis
- Every Week Is "Earth Science Week" at NASA
 |
 |
User Comments (0)
RSS Feeds